NASDAQ Framework: Apogee Therapeutics Inc.

Biotechnology company developing biologics for inflammatory diseases 1.
1: Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts. View Source
Apogee Therapeutics Inc. is a clinical-stage biotechnology company focused on developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory and immunology indications with high unmet need 2. The company’s innovative approach involves targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties 3. Apogee's two most advanced programs are APG777, a subcutaneous extended half-life monoclonal antibody for AD, and APG808, a similar antibody for COPD and asthma 45. The company aims to deliver meaningful benefits to patients underserved by current standard-of-care therapies 6.
2: Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, and asthma, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com. View Source3: Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, and asthma, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com. View Source4: Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts. View Source5: Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, and asthma, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com. View Source6: Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, and asthma, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com. View Source
UNKNOWN

The provided facts do not specify whether Apogee Therapeutics Inc. is still led by its founders or if the founders are heavily involved in the company's current operations.
MEDIUM RISK

Apogee Therapeutics Inc. is a clinical-stage biotechnology company, which inherently carries a certain level of financial risk due to the high costs associated with drug development and the uncertainty of clinical trial outcomes. While the company has shown progress in its pipeline and has raised substantial funds through public offerings 78, it is not yet profitable and relies on external funding to support its operations. Additionally, the recent insider sales by key executives 910 and the increase in short interest 11 suggest that there may be concerns about the company's near-term financial stability. However, the company's innovative approach and potential for high-impact treatments provide a counterbalance to these risks, placing it in the medium risk category.
7: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results View Source8: The shares were sold at a price of $37.6, valuing the transaction at approximately $225,402. This sale has adjusted the insider's stake in the company significantly. Apogee Therapeutics Inc currently has a market cap of approximately $2.143 billion. View Source9: On July 3, 2024, Carl Dambkowski, the Chief Medical Officer of Apogee Therapeutics Inc (NASDAQ:APGE), sold 5,995 shares of the company. The transaction was filed on the same day with the SEC. Following this transaction, the insider now owns 294,793 shares of Apogee Therapeutics Inc. View Source10: On July 5, 2024, Michael Henderson, CEO of Apogee Therapeutics Inc (NASDAQ:APGE), executed a sale of 15,000 shares of the company. The transaction was documented in an SEC Filing. Following this transaction, the insider now owns 1,474,487 shares of the company. View Source11: Short interest in Apogee Therapeutics Inc (NASDAQ:APGE) increased during the last reporting period, rising from 6.73M to 7.94M. This put 20.83% of the company's publicly available shares short. View Source
YES

Apogee Therapeutics Inc. has initiated a Phase 2 clinical trial of APG777, a novel subcutaneous half-life extended anti-IL-13 antibody for the treatment of atopic dermatitis and other inflammatory diseases 12.
12: Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases View Source
Apogee Therapeutics Inc.'s product roadmap for 2024 through 2026 focuses on advancing its pipeline of differentiated biologics targeting inflammatory and immunology indications with high unmet need. The company has initiated a Phase 2 clinical trial for APG777, a subcutaneous extended half-life monoclonal antibody for atopic dermatitis, with proof-of-concept data expected in the second half of 2025 13. Additionally, Apogee plans to expand the indications for APG777 to include asthma, with a Phase 2 trial anticipated to begin in 2025 14. The company is also progressing with APG808, another subcutaneous extended half-life monoclonal antibody, targeting chronic obstructive pulmonary disease and other inflammatory diseases, having dosed the first participant in a Phase 1 trial 15. This strategic focus on advancing clinical trials and expanding indications aims to address significant gaps in current treatment options and deliver meaningful benefits to patients 1617.
13: Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases View Source14: Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases View Source15: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results View Source16: Apogee Therapeutics is a clinical-stage biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology indications with high unmet need. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. The company’s two most advanced programs are APG777 and APG808, which are being initially developed for the treatment of AD and COPD, and asthma, respectively. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit www.apogeetherapeutics.com. View Source17: Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively. View Source